{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:31:52Z","timestamp":1793140312451,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BESO Biologic Research, Inc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fermented soy products have shown to possess inhibitory effects on prostate cancer (PCa). We evaluated the effect of a fermented soy beverage (Q-Can\u00ae), containing medium-chain triglycerides, ketones and soy isoflavones, among men with localized PCa prior to radical prostatectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a placebo-controlled, double-blind randomized trial of Q-Can\u00ae. Stratified randomization (Cancer of the Prostate Risk Assessment (CAPRA) score at diagnosis) was used to assign patients to receive Q-Can\u00ae or placebo for 2\u20135 weeks before RP. Primary endpoint was change in serum PSA from baseline to end-of-study. We assessed changes in other clinical and pathologic endpoints. The primary ITT analysis compared PSA at end-of-study between randomization arms using repeated measures linear mixed model incorporating baseline CAPRA risk strata.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We randomized 19 patients, 16 were eligible for analysis of the primary outcome. Mean age at enrollment was 61, 9(56.2%) were classified as low and intermediate risk, and 7(43.8%) high CAPRA risk. Among patients who received Q-Can\u00ae, mean PSA at baseline and end-of-study was 8.98(standard deviation, SD 4.07) and 8.02ng\/mL(SD 3.99) compared with 8.66(SD 2.71) to 9.53ng\/mL(SD 3.03), respectively, (Difference baseline \u2013 end-of-study,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.36). There were no significant differences in Gleason score, clinical stage, surgical margin status, or CAPRA score between treatment arms (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05), and no significant differences between treatment arms in end-of-study or change in lipids, testosterone and FACT-P scores (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Short exposure to Q-Can\u00ae among patients with localized PCa was not associated with changes in PSA levels, PCa characteristics including grade and stage or serum testosterone. Due to early termination from inability to recruit, study power, was not achieved.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-024-01483-y","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T04:02:24Z","timestamp":1714708944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy"],"prefix":"10.1186","volume":"24","author":[{"given":"Soum D.","family":"Lokeshwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ather","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa R.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Shuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ferencz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tassos C.","family":"Kyriakides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajahat Z.","family":"Mehal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Renzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Leapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"1483_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer statistics. 2022. CA: a cancer journal for clinicians. 2022;72(1):7\u201333. Epub 20220112. https:\/\/doi.org\/10.3322\/caac.21708. PubMed PMID: 35020204.","DOI":"10.3322\/caac.21708"},{"issue":"3","key":"1483_CR2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41391-022-00553-2","volume":"25","author":"N Gupta","year":"2022","unstructured":"Gupta N, Patel HD, Taylor J, Borin JF, Jacobsohn K, Kenfield SA, et al. Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes. Prostate Cancer Prostatic Dis. 2022;25(3):444\u201352. https:\/\/doi.org\/10.1038\/s41391-022-00553-2. Epub 20220705.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"1483_CR3","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/ajcn\/nqab365","volume":"115","author":"S Loeb","year":"2022","unstructured":"Loeb S, Fu BC, Bauer SR, Pernar CH, Chan JM, Van Blarigan EL, et al. Association of plant-based diet index with prostate cancer risk. Am J Clin Nutr. 2022;115(3):662\u201370. https:\/\/doi.org\/10.1093\/ajcn\/nqab365. PubMed PMID: 34791008; PubMed Central PMCID: PMC8895206.","journal-title":"Am J Clin Nutr"},{"key":"1483_CR4","doi-asserted-by":"publisher","unstructured":"Fraser GE, Jaceldo-Siegl K, Orlich M, Mashchak A, Sirirat R, Knutsen S. Dairy, soy, and risk of breast cancer: those confounded milks. Int J Epidemiol. 2020. Epub 2020\/02\/26. https:\/\/doi.org\/10.1093\/ije\/dyaa007. PubMed PMID: 32095830.","DOI":"10.1093\/ije\/dyaa007"},{"issue":"11","key":"1483_CR5","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/cncr.30614","volume":"123","author":"O Kucuk","year":"2017","unstructured":"Kucuk O. Soy foods, isoflavones, and breast cancer. Cancer. 2017;123(11):1901\u20133. https:\/\/doi.org\/10.1002\/cncr.30614. Epub 2017\/03\/07.","journal-title":"Cancer"},{"issue":"1","key":"1483_CR6","first-page":"73","volume":"8","author":"YC Wu","year":"2015","unstructured":"Wu YC, Zheng D, Sun JJ, Zou ZK, Ma ZL. Meta-analysis of studies on breast cancer risk and diet in Chinese women. Int J Clin Exp Med. 2015;8(1):73\u201385. Epub 2015\/03\/19. PubMed PMID: 25784976; PubMed Central PMCID: PMC4358431.","journal-title":"Int J Clin Exp Med"},{"issue":"11","key":"1483_CR7","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1002\/cncr.30615","volume":"123","author":"FF Zhang","year":"2017","unstructured":"Zhang FF, Haslam DE, Terry MB, Knight JA, Andrulis IL, Daly MB, et al. Dietary isoflavone intake and all-cause mortality in breast cancer survivors: the breast Cancer Family Registry. Cancer. 2017;123(11):2070\u20139. https:\/\/doi.org\/10.1002\/cncr.30615. Epub 2017\/03\/07.","journal-title":"Cancer"},{"key":"1483_CR8","doi-asserted-by":"publisher","unstructured":"Ouyang X, Chen Y, Tejaswi BS, Arumugam S, Secor E, Weiss TR et al. Fermented soy drink (Q-CAN\u00ae PLUS) induces apoptosis and reduces viability of Cancer cells. Nutr Cancer. 2022:1\u201310. Epub 20220523. https:\/\/doi.org\/10.1080\/01635581.2022.2077385. PubMed PMID: 35603899.","DOI":"10.1080\/01635581.2022.2077385"},{"issue":"2","key":"1483_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bcp.2004.09.025","volume":"69","author":"SJ Su","year":"2005","unstructured":"Su SJ, Yeh TM, Chuang WJ, Ho CL, Chang KL, Cheng HL, et al. The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem Pharmacol. 2005;69(2):307\u201318. https:\/\/doi.org\/10.1016\/j.bcp.2004.09.025. Epub 20041119.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1483_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000499246","volume":"14","author":"A Battaglia","year":"2020","unstructured":"Battaglia A, Devos G, Boeckx G, Goeman L, Tosco L, de Meerleer G, et al. Prostate-specific Antigen Modulatory Effect of a fermented soy supplement for patients with an elevated risk of prostate Cancer: a Non-randomized, Retrospective Observational Registration. Curr Urol. 2020;14(3):142\u20139. Epub 20201013. https:\/\/doi.org\/10.1159\/000499246. PubMed PMID: 33224007; PubMed Central PMCID: PMC7659407.","journal-title":"Curr Urol"},{"issue":"Supplement1","key":"1483_CR11","first-page":"nzz035","volume":"3","author":"W Mehal","year":"2019","unstructured":"Mehal W, Secor E, Weiss T, Fields M, Leapman M, Ali A. Isoflavone Stability Quality Control Assessment of Q-CAN\u00ae plus, a Novel Fermented Soy Beverage (P12-034-19). Curr Developments Nutr. 2019;3(Supplement1):nzz035. P12-4-19.","journal-title":"Curr Developments Nutr"},{"issue":"3","key":"1483_CR12","doi-asserted-by":"publisher","first-page":"e1000251","DOI":"10.1371\/journal.pmed.1000251","volume":"7","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7(3):e1000251. https:\/\/doi.org\/10.1371\/journal.pmed.1000251. Epub 20100324.","journal-title":"PLoS Med"},{"key":"1483_CR13","doi-asserted-by":"publisher","unstructured":"Applegate CC, Rowles JL, Ranard KM, Jeon S, Erdman JW. Soy Consumption and the Risk of Prostate Cancer: An Updated Systematic Review and Meta-Analysis. Nutrients. 2018;10(1). Epub 20180104. https:\/\/doi.org\/10.3390\/nu10010040. PubMed PMID: 29300347; PubMed Central PMCID: PMC5793268.","DOI":"10.3390\/nu10010040"},{"issue":"11","key":"1483_CR14","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s10552-015-0659-4","volume":"26","author":"LE Hackshaw-McGeagh","year":"2015","unstructured":"Hackshaw-McGeagh LE, Perry RE, Leach VA, Qandil S, Jeffreys M, Martin RM, et al. A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality. Cancer Causes Control. 2015;26(11):1521\u201350. https:\/\/doi.org\/10.1007\/s10552-015-0659-4. Epub 20150909.","journal-title":"Cancer Causes Control"},{"issue":"6","key":"1483_CR15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/01635581.2011.582221","volume":"63","author":"B Lazarevic","year":"2011","unstructured":"Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, et al. Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind phase 2 clinical trial. Nutr Cancer. 2011;63(6):889\u201398. https:\/\/doi.org\/10.1080\/01635581.2011.582221. Epub 20110629.","journal-title":"Nutr Cancer"},{"issue":"2","key":"1483_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/pros.10362","volume":"59","author":"NB Kumar","year":"2004","unstructured":"Kumar NB, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004;59(2):141\u20137. https:\/\/doi.org\/10.1002\/pros.10362. PubMed PMID: 15042614.","journal-title":"Prostate"},{"issue":"7","key":"1483_CR17","doi-asserted-by":"publisher","first-page":"e68331","DOI":"10.1371\/journal.pone.0068331","volume":"8","author":"JM Hamilton-Reeves","year":"2013","unstructured":"Hamilton-Reeves JM, Banerjee S, Banerjee SK, Holzbeierlein JM, Thrasher JB, Kambhampati S, et al. Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial. PLoS ONE. 2013;8(7):e68331. https:\/\/doi.org\/10.1371\/journal.pone.0068331. Epub 20130712.","journal-title":"PLoS ONE"},{"issue":"10","key":"1483_CR18","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1080\/01635581.2022.2077385","volume":"74","author":"X Ouyang","year":"2022","unstructured":"Ouyang X, Chen Y, Tejaswi BS, Arumugam S, Secor E, Weiss TR, et al. Fermented soy drink (Q-CAN(R) PLUS) induces apoptosis and reduces viability of Cancer cells. Nutr Cancer. 2022;74(10):3670\u20138. https:\/\/doi.org\/10.1080\/01635581.2022.2077385. Epub 2022\/05\/24.","journal-title":"Nutr Cancer"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01483-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-024-01483-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01483-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T04:06:01Z","timestamp":1714709161000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-024-01483-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1483"],"URL":"https:\/\/doi.org\/10.1186\/s12894-024-01483-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3240223\/v1","asserted-by":"object"}]},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations. All patients provided written informed consent prior to administering any study procedures. Interim analysis and monitoring were performed by the principle investigators and presented and reviewed by the independent Data Safety Monitoring Board. This trial was approved by the Yale University institutional review board, Protocol Number: 2000020868.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}